B3GNT4

Summary

B3GNT4 (UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4, HGNC:15683) is a protein-coding gene on chromosome 12q24.31, encoding N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 4 (Q9C0J1). Beta-1,3-N-acetylglucosaminyltransferase involved in the synthesis of poly-N-acetyllactosamine.

This gene encodes a member of the beta-1,3-N-acetylglucosaminyltransferase protein family. The encoded enzyme is involved in the biosynthesis of poly-N-acetyllactosamine chains and prefers lacto-N-neotetraose as a substrate. It is a type II transmembrane protein.

Source: NCBI Gene 79369 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 137 total — 1 pathogenic, 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_030765

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15683
Approved symbol	B3GNT4
Name	UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4
Location	12q24.31
Locus type	gene with protein product
Status	Approved
Aliases	B3GN-T4, beta3Gn-T4
Ensembl gene	ENSG00000176383
Ensembl biotype	protein_coding
OMIM	605864
Entrez	79369

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 4 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000324189, ENST00000535274, ENST00000537991, ENST00000538257, ENST00000545141, ENST00000546192

RefSeq mRNA: 2 — MANE Select: NM_030765 NM_001330492, NM_030765

CCDS: CCDS81751, CCDS9227

Canonical transcript exons

ENST00000324189 — 3 exons

Exon	Start	End
ENSE00001285488	122203709	122203801
ENSE00001414052	122206318	122208952
ENSE00003818734	122204522	122204684

Expression profiles

Bgee: expression breadth ubiquitous, 181 present calls, max score 92.87.

FANTOM5 (CAGE): breadth broad, TPM avg 1.0555 / max 51.1071, expressed in 447 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
128513	0.6531	334
128514	0.4024	235

Top tissues by expression

261 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	92.87	gold quality
olfactory bulb	UBERON:0002264	88.70	gold quality
type B pancreatic cell	CL:0000169	86.29	gold quality
secondary oocyte	CL:0000655	82.45	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.56	gold quality
upper arm skin	UBERON:0004263	79.24	gold quality
pancreatic ductal cell	CL:0002079	78.99	silver quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	78.93	gold quality
parotid gland	UBERON:0001831	78.36	gold quality
cortical plate	UBERON:0005343	78.04	gold quality
nasal cavity epithelium	UBERON:0005384	77.05	gold quality
diaphragm	UBERON:0001103	76.93	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	76.53	gold quality
prefrontal cortex	UBERON:0000451	76.31	gold quality
triceps brachii	UBERON:0001509	75.57	gold quality
quadriceps femoris	UBERON:0001377	75.48	gold quality
vastus lateralis	UBERON:0001379	75.32	gold quality
cerebellar cortex	UBERON:0002129	74.72	gold quality
cerebellar hemisphere	UBERON:0002245	74.66	gold quality
right hemisphere of cerebellum	UBERON:0014890	74.51	gold quality
inferior olivary complex	UBERON:0002127	74.50	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	74.41	gold quality
frontal cortex	UBERON:0001870	74.37	gold quality
lateral globus pallidus	UBERON:0002476	74.33	silver quality
cerebellum	UBERON:0002037	74.32	gold quality
thymus	UBERON:0002370	74.26	gold quality
mucosa of urinary bladder	UBERON:0001259	73.93	gold quality
Brodmann (1909) area 9	UBERON:0013540	73.87	gold quality
right frontal lobe	UBERON:0002810	73.79	gold quality
cervix squamous epithelium	UBERON:0006922	73.75	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-CURD-10	no	74.95
E-ANND-3	no	1.64

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

14 targeting B3GNT4, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-4424	98.91	70.33	1145
HSA-MIR-4715-5P	97.62	67.47	506
HSA-MIR-610	96.84	67.98	905
HSA-MIR-4653-3P	96.26	67.03	725

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
mus_musculus	B3gnt4	ENSMUSG00000029431
rattus_norvegicus	B3gnt4	ENSRNOG00000085730
drosophila_melanogaster	brn	FBGN0000221
caenorhabditis_elegans		WBGENE00000270
caenorhabditis_elegans		WBGENE00007096
caenorhabditis_elegans		WBGENE00017653

Paralogs (15): B3GNT7 (ENSG00000156966), B3GALT2 (ENSG00000162630), B3GALNT2 (ENSG00000162885), B3GALNT1 (ENSG00000169255), B3GNT2 (ENSG00000170340), B3GALT1 (ENSG00000172318), B3GALT6 (ENSG00000176022), B3GNT5 (ENSG00000176597), B3GNT8 (ENSG00000177191), B3GNT3 (ENSG00000179913), B3GALT5 (ENSG00000183778), B3GNT6 (ENSG00000198488), B3GALT9 (ENSG00000214654), B3GALT4 (ENSG00000235863), B3GNT9 (ENSG00000237172)

Protein

Protein identifiers

N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase 4 — Q9C0J1 (reviewed: Q9C0J1)

Alternative names: UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4

All UniProt accessions (2): Q9C0J1, A0A2R8YCM2

UniProt curated annotations — full annotation on UniProt →

Function. Beta-1,3-N-acetylglucosaminyltransferase involved in the synthesis of poly-N-acetyllactosamine. Has activity for type 2 oligosaccharides.

Subcellular location. Golgi apparatus membrane.

Tissue specificity. Mainly expressed in brain tissues such as whole brain, hippocampus, amygdala, cerebellum and caudate nucleus. Also expressed in colon, esophagus and kidney.

Pathway. Protein modification; protein glycosylation.

Similarity. Belongs to the glycosyltransferase 31 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9C0J1-1	1	yes
Q9C0J1-2	2

RefSeq proteins (2): NP_001317421, NP_110392* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002659	Glyco_trans_31	Family

Pfam: PF01762

Catalyzed reactions (Rhea), 1 shown:

• a beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + UDP-N-acetyl-alpha-D-glucosamine = an N-acetyl-beta-D-glucosaminyl-(1->3)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosaminyl derivative + UDP + H(+) (RHEA:14389)

UniProt features (14 total): sequence conflict 4, sequence variant 3, topological domain 2, chain 1, transmembrane region 1, region of interest 1, glycosylation site 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9C0J1-F1	87.51	0.75

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (1): 192

Function

Pathways and Gene Ontology

Reactome pathways

9 pathways

ID	Pathway
R-HSA-2022854	Keratan sulfate biosynthesis
R-HSA-913709	O-linked glycosylation of mucins
R-HSA-1430728	Metabolism
R-HSA-1630316	Glycosaminoglycan metabolism
R-HSA-1638074	Keratan sulfate/keratin metabolism
R-HSA-392499	Metabolism of proteins
R-HSA-5173105	O-linked glycosylation
R-HSA-597592	Post-translational protein modification
R-HSA-71387	Metabolism of carbohydrates and carbohydrate derivatives

MSigDB gene sets: 62 (showing top): GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_AMINOGLYCAN_BIOSYNTHETIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, GOBP_AMINOGLYCAN_METABOLIC_PROCESS, GOBP_PROTEIN_O_LINKED_GLYCOSYLATION_VIA_N_ACETYL_GALACTOSAMINE, GOBP_PROTEIN_O_LINKED_GLYCOSYLATION, GOBP_GLYCOPROTEIN_METABOLIC_PROCESS, SHEN_SMARCA2_TARGETS_DN, REACTOME_METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES, KEGG_GLYCOSPHINGOLIPID_BIOSYNTHESIS_LACTO_AND_NEOLACTO_SERIES, GOMF_HEXOSYLTRANSFERASE_ACTIVITY, chr12q24, GOMF_BETA_1_3_GALACTOSYLTRANSFERASE_ACTIVITY, GOMF_GLYCOSYLTRANSFERASE_ACTIVITY, GOMF_GALACTOSYLTRANSFERASE_ACTIVITY

GO Biological Process (5): protein O-linked glycosylation (GO:0006493), protein O-linked glycosylation via N-acetylgalactosamine (GO:0016266), keratan sulfate proteoglycan biosynthetic process (GO:0018146), poly-N-acetyllactosamine biosynthetic process (GO:0030311), obsolete protein glycosylation (GO:0006486)

GO Molecular Function (5): N-acetyl-beta-D-glucosaminide beta-(1,3)-galactosyltransferase activity (GO:0008499), N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase activity (GO:0008532), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757), hexosyltransferase activity (GO:0016758)

GO Cellular Component (3): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-7 pathways:

Category	Pathways
Keratan sulfate/keratin metabolism	1
O-linked glycosylation	1
Metabolism of carbohydrates and carbohydrate derivatives	1
Glycosaminoglycan metabolism	1
Post-translational protein modification	1
Metabolism of proteins	1
Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
glycoprotein biosynthetic process	1
protein O-linked glycosylation	1
proteoglycan biosynthetic process	1
keratan sulfate proteoglycan metabolic process	1
aminoglycan biosynthetic process	1
poly-N-acetyllactosamine metabolic process	1
UDP-galactosyltransferase activity	1
beta-1,3-galactosyltransferase activity	1
acetylglucosaminyltransferase activity	1
catalytic activity	1
transferase activity	1
glycosyltransferase activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

474 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
B3GNT4	TMEM171	Q8WVE6	620
B3GNT4	UBE2Q2	Q8WVN8	597
B3GNT4	A1CF	Q9NQ94	568
B3GNT4	PLAU	P00749	543
B3GNT4	TRIM46	Q7Z4K8	541
B3GNT4	SFMBT1	Q9UHJ3	497
B3GNT4	HNF4G	Q14541	446
B3GNT4	NTPCR	Q9BSD7	444
B3GNT4	BAZ1B	Q9UIG0	434
B3GNT4	B4GALT2	O60909	432
B3GNT4	FAM222A	Q5U5X8	430
B3GNT4	CDK2AP1	O14519	426
B3GNT4	SLC22A11	Q9NSA0	423
B3GNT4	SLC17A1	Q14916	418
B3GNT4	INHBB	P09529	415

IntAct

5 interactions, top by confidence:

A	B	Type	Score
CUL4B	APBB1	psi-mi:“MI:0914”(association)	0.350
PCDHB3	ESYT2	psi-mi:“MI:0914”(association)	0.350
ECEL1	ADAM10	psi-mi:“MI:0914”(association)	0.350
GOLM1	B3GNT4	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (5): B3GNT4 (Affinity Capture-MS), B3GNT4 (Affinity Capture-MS), B3GNT4 (Positive Genetic), B3GNT4 (Affinity Capture-RNA), B3GNT4 (Affinity Capture-MS)

ESM2 similar proteins: A7MB73, O00587, O09008, O09009, O09010, O12971, O12972, O19058, O97583, P04180, P17405, P21217, P52849, P52850, P56433, Q08758, Q0V8G3, Q0VD19, Q11128, Q11131, Q17QZ8, Q1RLK6, Q2KJ92, Q4R942, Q5IS64, Q5T4B2, Q63148, Q6IQX7, Q6XQG9, Q6ZMM2, Q8BH73, Q8HYJ4, Q8HYJ5, Q8HYJ7, Q8HZR3, Q8IZ52, Q8N135, Q8NES3, Q924T4, Q9BZG2

Diamond homologs: A8MXE2, O43825, O54904, O54905, O75752, O88178, O96024, Q1RLK6, Q5HZL5, Q5JCS9, Q5R5Y3, Q5RAL7, Q66H69, Q6AY39, Q6DE15, Q6P3P5, Q793U7, Q7JK24, Q7JK25, Q7JK26, Q7T3S5, Q864U6, Q864U8, Q8BGY6, Q8R3I9, Q920V1, Q95US5, Q99NB2, Q9BYG0, Q9C0J1, Q9JI67, Q9MYM7, Q9N293, Q9N294, Q9N295, Q9Y2A9, Q9Y2C3, Q9Y5Z6, Q9Z0F0, Q3USF0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

137 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	107
Likely benign	15
Benign	5

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
57611	GRCh38/hg38 12q24.31(chr12:121471000-122459718)x1	Pathogenic
3250381	NM_001371333.1(DIABLO):c.718T>C (p.Ter240Arg)	Likely pathogenic

SpliceAI

444 predictions. Top by Δscore:

Variant	Effect	Δscore
12:122203801:GGTA:G	donor_loss	0.9900
12:122203803:T:G	donor_loss	0.9900
12:122206401:G:GT	donor_gain	0.9800
12:122208578:C:A	acceptor_loss	0.9800
12:122208578:C:CC	acceptor_gain	0.9800
12:122208578:CT:C	acceptor_loss	0.9800
12:122208579:T:G	acceptor_loss	0.9800
12:122203802:G:GG	donor_gain	0.9700
12:122204653:G:T	donor_gain	0.9700
12:122208575:CGC:C	acceptor_gain	0.9700
12:122208580:G:C	acceptor_loss	0.9500
12:122204653:G:GT	donor_gain	0.9200
12:122208582:C:CT	acceptor_gain	0.9100
12:122205724:T:A	donor_gain	0.9000
12:122208573:TGCGC:T	acceptor_gain	0.9000
12:122208436:T:TA	donor_gain	0.8900
12:122204680:CAAAG:C	donor_loss	0.8800
12:122204682:AAG:A	donor_loss	0.8800
12:122204683:AGGTC:A	donor_loss	0.8800
12:122204684:G:GC	donor_loss	0.8800
12:122204686:T:A	donor_loss	0.8800
12:122206312:TTGCA:T	acceptor_loss	0.8800
12:122206313:TGCAG:T	acceptor_loss	0.8800
12:122206314:GCAG:G	acceptor_loss	0.8800
12:122206315:CAG:C	acceptor_loss	0.8800
12:122206316:AG:A	acceptor_gain	0.8800
12:122206317:GG:G	acceptor_gain	0.8800
12:122203800:AG:A	donor_gain	0.8700
12:122203801:GG:G	donor_gain	0.8700
12:122204295:T:TA	donor_gain	0.8700

AlphaMissense

2438 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:122206839:G:C	K196N	0.995
12:122206839:G:T	K196N	0.995
12:122207165:A:T	D305V	0.994
12:122207165:A:G	D305G	0.992
12:122207166:T:A	D305E	0.992
12:122207166:T:G	D305E	0.992
12:122207165:A:C	D305A	0.991
12:122206626:G:C	K125N	0.988
12:122206626:G:T	K125N	0.988
12:122207029:T:C	Y260H	0.988
12:122207096:T:A	V282D	0.988
12:122206651:C:A	R134S	0.987
12:122207032:T:C	F261L	0.987
12:122207034:C:A	F261L	0.987
12:122207034:C:G	F261L	0.987
12:122207162:A:T	D304V	0.987
12:122207164:G:C	D305H	0.987
12:122206720:T:C	F157L	0.986
12:122206722:C:A	F157L	0.986
12:122206722:C:G	F157L	0.986
12:122207030:A:G	Y260C	0.986
12:122207225:T:C	F325S	0.986
12:122207006:C:A	P252H	0.985
12:122207296:C:G	H349D	0.985
12:122206801:T:A	W184R	0.984
12:122206801:T:C	W184R	0.984
12:122206807:T:C	F186L	0.983
12:122206809:C:A	F186L	0.983
12:122206809:C:G	F186L	0.983
12:122207090:G:A	G280E	0.983

dbSNP variants (sampled 300 via entrez): RS1000342979 (12:122203752 C>A,T), RS1000839607 (12:122203989 C>T), RS1000992958 (12:122203941 C>G,T), RS1001178 (12:122206498 T>A,C), RS1001274768 (12:122204202 G>A), RS1001668300 (12:122205945 A>G), RS1001737809 (12:122202568 A>G), RS1001950631 (12:122206166 G>A,C), RS1002083709 (12:122208866 A>C), RS1002280663 (12:122207703 C>T), RS1002552024 (12:122207000 C>A,G,T), RS1002938470 (12:122205260 G>A,C,T), RS1003776980 (12:122202389 C>A), RS1004131039 (12:122208673 C>A,T), RS1004142403 (12:122208935 T>C)

Disease associations

OMIM: gene MIM:605864 | disease phenotypes: MIM:614152

GenCC curated gene-disease

Mondo (3): autosomal dominant nonsyndromic hearing loss 64 (MONDO:0013593), nonsyndromic genetic hearing loss (MONDO:0019497), hearing loss disorder (MONDO:0005365)

Orphanet (2): Rare autosomal dominant non-syndromic sensorineural deafness type DFNA (Orphanet:90635), Rare non-syndromic genetic deafness (Orphanet:87884)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001791_6	Urate levels	3.000000e-08
GCST90020025_115	Waist-to-hip ratio adjusted for BMI	1.000000e-08
GCST90020027_1193	Waist-hip index	3.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004531	urate measurement
EFO:0007788	BMI-adjusted waist-hip ratio

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D034381	Hearing Loss	C09.218.458.341; C10.597.751.418.341; C23.888.592.763.393.341
C580334	Nonsyndromic Deafness (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5465353 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases methylation	2
1-cyclopropyl-4-(4-((5-methyl-3-(3-(4-(trifluoromethoxy)phenyl)-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl)methyl)pyridin-2-yl)piperazine	decreases reaction, increases expression	1
fluorene-9-bisphenol	increases expression	1
abrine	decreases expression	1
licochalcone B	increases expression	1
Rosiglitazone	increases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Amphotericin B	increases expression	1
Oxygen	decreases reaction, increases expression	1
Plant Extracts	decreases expression, affects cotreatment	1
Smoke	decreases expression	1
Thiram	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Uric Acid	affects abundance	1
Aflatoxin B1	increases methylation	1
Okadaic Acid	increases expression	1
Acrylamide	increases expression	1
Particulate Matter	decreases expression, increases abundance	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5345419	Binding	Inhibition of B3GNT4 (unknown origin) using Beta-lactose and UDP-GlcNAc as substrate incubated for 1.5 to 2 hrs by UDP-Glo based analysis	Imidazolone as an Amide Bioisostere in the Development of β-1,3-N-Acetylglucosaminyltransferase 2 (B3GNT2) Inhibitors. — J Med Chem

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SE48	HAP1 B3GNT4 (-) 1	Cancer cell line	Male
CVCL_XL87	HAP1 B3GNT4 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00205881	PHASE4	COMPLETED	Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System
NCT00331539	PHASE4	UNKNOWN	Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant
NCT00424307	PHASE4	UNKNOWN	Bilateral Cochlear Implant Benefit in Young Children
NCT00765635	PHASE4	COMPLETED	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
NCT03321006	PHASE4	COMPLETED	Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT01499901	PHASE3	WITHDRAWN	Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children
NCT02561091	PHASE3	COMPLETED	AM-111 in the Treatment of Acute Inner Ear Hearing Loss
NCT03331627	PHASE3	COMPLETED	Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT05532657	PHASE3	ACTIVE_NOT_RECRUITING	ACHIEVE Brain Health Follow-Up Study
NCT00013455	PHASE2	COMPLETED	Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
NCT00323427	PHASE2	COMPLETED	Clinical Trial of the Living Well With Hearing Loss Workshop
NCT00552786	PHASE2	COMPLETED	Antioxidation Medication for Noise-induced Hearing Loss
NCT00802425	PHASE2	COMPLETED	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
NCT01139281	PHASE2	COMPLETED	The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01451853	PHASE2	UNKNOWN	SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01588925	PHASE2	COMPLETED	Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT02832128	PHASE2	COMPLETED	Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
NCT04915183	PHASE2	RECRUITING	Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT05258773	PHASE2	COMPLETED	Evaluation of the Presence of SENS-401 in the Perilymph
NCT06340633	PHASE2	RECRUITING	SPI-1005 in Adults Receiving Cochlear Implant
NCT00582946	PHASE1	COMPLETED	Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
NCT00584155	PHASE1	WITHDRAWN	Protection From Cisplatin Ototoxicity by Lactated Ringers
NCT01206829	PHASE1	UNKNOWN	Hearing Impairment, Cognitive Therapy and Coping
NCT01256229	PHASE1	COMPLETED	Outcomes In Children With Developmental Delay And Deafness
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01452607	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT04041440	PHASE1	COMPLETED	Speech Recognition Training in Children With Hearing Loss
NCT07218913	PHASE1	RECRUITING	Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
NCT01802190	Not specified	TERMINATED	Prevalence of POU4F3 and SLC17A8 Mutations
NCT00486577	PHASE2/PHASE3	COMPLETED	Chronic Electrical Stimulation of the Auditory Cortex for Intractable Tinnitus
NCT00789061	PHASE2/PHASE3	UNKNOWN	Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation
NCT01423409	PHASE2/PHASE3	COMPLETED	Multicenter Trial Assessing an Innovative VAS of Pain Among Deaf People
NCT05786378	PHASE2/PHASE3	UNKNOWN	Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
NCT01108601	PHASE1/PHASE2	UNKNOWN	Transtympanic Ringer’s Lactate for the Prevention of Cisplatin Ototoxicity
NCT01621256	PHASE1/PHASE2	COMPLETED	Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss
NCT06370351	PHASE1/PHASE2	RECRUITING	A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
NCT06545175	PHASE1/PHASE2	RECRUITING	Intracochlear Application of VSF1.01 for the Reduction of Cochlear Implant Surgery Related Trauma
NCT07304024	PHASE1/PHASE2	RECRUITING	A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound